Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349267 · ClinicalTrials.gov registry record · Phase 1
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 8
- Study locations
NCT04349267: Completed Phase 1 study of Advanced Solid Tumor, sponsored by Bristol-Myers Squibb.
NCT04349267 is a Phase 1 study of Advanced Solid Tumor that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 44 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04349267, a Phase 1 study of Advanced Solid Tumor, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
Primary Outcome
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention. Serious Adverse Event (SAE) is defined as any untoward me
Conditions Studied
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL cetuximab
- BIOLOGICAL BMS-986315
Study Locations (8)
South Dakota
- Local Institution - 0028 - Sioux Falls
Tennessee
- Local Institution - 0001 - Germantown
Alberta
- Local Institution - 0014 - Edmonton
British Columbia
- Local Institution - 0011 - Vancouver
Ontario
- Local Institution - 0004 - Toronto
Quebec
- Local Institution - 0005 - Montreal
Other
- Local Institution - 0013 - Ottawa
Mexico City
- Local Institution - Mexico City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 1 |
What the finished NCT04349267 record still lists
NCT04349267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which nivolumab is the first listed.
NCT04349267 lists 8 locations in 8 states (South Dakota, Tennessee, Alberta).
Frequently Asked Questions
What is clinical trial NCT04349267 about?
NCT04349267 is a clinical study titled "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
What is the current status of trial NCT04349267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2020-07-14. Estimated completion is 2024-08-22.
What conditions does trial NCT04349267 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04349267?
The interventions under investigation include: nivolumab (BIOLOGICAL), cetuximab (BIOLOGICAL), BMS-986315 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04349267?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04349267 being conducted?
This trial has 8 study locations across South Dakota, Tennessee, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04349267's enrollment target sits among peer trials
44 164th of 189 higher than 25 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI